Canadianbull1324
$RVVTF Topics directly related to nerve agent exposure and defence research were core focal points of the recent Defence Growth Forum, which took place on October 28–29, 2026, in Medicine Hat, Alberta.
While specific commercial entity names like Revive Therapeutics (CSE: RVV) or their specific drug candidate bucillamine were not explicitly broadcasted as standalone session titles, their exact research context took center stage during the forum's most prominent technical briefings.
8